Tesetaxel

Tesetaxel
Clinical data
ATC code none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number 333754-36-2 YesY
PubChem (CID) 6918574
ChemSpider 5293771 N
UNII UG97LO5M8Y YesY
Chemical and physical data
Formula C46H60FN3O13
Molar mass 881.98 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Tesetaxel (DJ-927) is a drug being investigated for chemotherapy of various types of cancer, including breast cancer,[1] gastric cancer,[2] and other solid tumours.[3]

References

  1. Clinical trial number NCT01609127 for "Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer" at ClinicalTrials.gov
  2. Clinical trial number NCT01348009 for "Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer" at ClinicalTrials.gov
  3. Saif, M. W.; Sarantopoulos, J.; Patnaik, A.; Tolcher, A. W.; Takimoto, C.; Beeram, M. (2011). "Tesetaxel, a new oral taxane, in combination with capecitabine: A phase I, dose-escalation study in patients with advanced solid tumors". Cancer Chemotherapy and Pharmacology. 68 (6): 1565–1573. doi:10.1007/s00280-011-1639-3. PMID 21547572.


This article is issued from Wikipedia - version of the 9/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.